Comparison of Presentation and Outcome for Patients 18 to 40 and 60 to 70 Years Old With Solid Renal Masses

Gillett, Michael D.; Cheville, John C.; Karnes, R. Jeffrey; Lohse, Christine M.; Kwon, Eugene D.; Leibovich, Bradley C.; Zincke, Horst; Blute, Michael L.

doi:10.1097/01.ju.0000158157.57981.80

Cited by 81 publications

(76 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Specifically, Hollingsworth et al [16] reported a lack of statistically significant difference between young and old individuals in regard to CSM considering stages T1-2, N0, M0 RCC. While, Thompson et al [17] and Gillett et al [18] did not observe a significant CSM disadvantage for individuals with older age considering localized (T1-4, N0, M0) and non-localized (any T, N1 or M1) RCC.…”

Section: Cuaj -Original Research Bandini Et Al Effect Of Age On Cancementioning

confidence: 94%

The effect of age on cancer-specific mortality in patients with small renal masses: A population-based analysis

Bandini

Marchioni²,

Pompe³

et al. 2018

CUAJ

View full text Add to dashboard Cite

Introduction: Contemporary data regarding the effect of age, especially in the elderly patients, on cancer-specific mortality (CSM) for pT1a renal cell cancer (RCC) are lacking. The objective of the current study is to evaluate CSM in a large population-based cohort of surgically treated pT1a RCC patients according to age groups. Methods: Within the Surveillance Epidemiology and End Results database (2000-2013), we identified 37 121 pT1a RCC patients who underwent either partial or radical nephrectomy. The population was stratified into five groups according to decades: <50, 50-59, 60-69, 70-79, and ≥80 years. The effect of age on CSM was evaluated using competing risks regression models according to Fuhrman grade (FG). Analyses were repeated in clear-cell RCC (ccRCC). Results: Patients aged 50-59 (9615), 60-69 (10 762), 70-79 (7096), and ≥80 (1789) years demonstrated higher rate of CSM compared to patients aged <50 (7856) yrs (hazard ratios [HR] 2.11, 3.04, 4.47, and 7.56, respectively; all p<0.001). The effect of age on CSM in FG 1-2 patients resulted in HRs ranged from 2.01-8.23 for the same age decades (all p< 0.001). Similarly, the effect of age on CSM in FG 3-4 patients resulted in HRs ranged from 2.38-5.92, respectively (all p< 0.001). Virtually the same results were recorded in ccRCC patients. Conclusions: Older age is associated with higher CSM in surgically treated patients with pT1a RCC. This effect seems to be more pronounced in patient with FG 1-2 disease. This observation should be considered in treatment decision-making in elderly patients.

show abstract

Section: Cuaj -Original Research Bandini Et Al Effect Of Age On Cancementioning

confidence: 94%

The effect of age on cancer-specific mortality in patients with small renal masses: A population-based analysis

Bandini

Marchioni²,

Pompe³

et al. 2018

CUAJ

View full text Add to dashboard Cite

show abstract

“…Both used an age cutoff of 40 years, which was consistent with cut-offs tested in previous studies of RCC and with cut-offs used in studies of other cancers. 7,14 However, no biological basis supports the validity of this cut-off in RCC. Based on the sample size and methodological limitations of the previous studies, we sought to assess the effect of age in one of the largest multiinstitutional cohorts of patients treated with either partial or radical nephrectomies.…”

Section: Discussionmentioning

confidence: 99%

Age at diagnosis is a determinant factor of renal cell carcinoma– specific survival in patients treated with nephrectomy

Karakiewicz

Jeldres

Suardi

et al. 2008

CUAJ

View full text Add to dashboard Cite

Objective: Based on combined data for 4880 patients, 2 previous studies reported that advanced age is a predictor of increased renal cell carcinoma-specific mortality (RCC-SM). We explored the effect of age in cubic spline analyses to identify the age groups with the most elevated risk for renal cell carcinoma (RCC). Methods:Our study included 3595 patients from 14 European centres who had partial or radical nephrectomies. We used the Kaplan-Meier method to compile life tables, and we performed Cox regression analyses to assess RCC-SM. Covariates included age at diagnosis, sex, TNM (tumour, node, metastasis) stage, tumour size, Fuhrman grade, symptom classification and histological subtype.

show abstract

“…"Therapy" for RCC patients often includes surgical removal of the affected organ and the surrounding tissues with additional medical intervention (Gillett et al, 2005). However, if the disease has spread beyond the kidney capsule, the prognosis of the patients is generally poor.…”

Section: Introductionmentioning

confidence: 99%

Docetaxel enhances apoptosis and G2/M cell cycle arrest by suppressing mitogen-activated protein kinase signaling in human renal clear cell carcinoma

2016

View full text Add to dashboard Cite

ABSTRACT. Tremendous efforts have been made in renal cell carcinoma (RCC) patients' research; however, clinical findings in patients have been disappointing. The aims of our study were to identify better or alternative therapeutic methods that can reverse chemotherapy resistance and to enhance sensitivity to docetaxel (DOX)-based chemotherapy drugs. We evaluated the anti-proliferative effect of DOX against RCC cells. DOX was found to suppress proliferation of RCC cells under in vitro and in vivo settings. Flow cytometric analysis revealed that DOX suppressed cell growth by induction of both apoptosis and G2/M cell cycle arrest in a dosedependent manner. Various patterns of gene expression were observed by cluster analysis. In addition, based on network analysis using the ingenuity pathway analysis software, DOX was found to suppress phosphorylation of extracellular signal-regulated kinase 1/2 and p38, suggesting that the mitogen-activated protein kinase signaling pathway plays a vital role in the anti-proliferative effect of DOX against RCC.

show abstract

Comparison of Presentation and Outcome for Patients 18 to 40 and 60 to 70 Years Old With Solid Renal Masses

Cited by 81 publications

References 18 publications

The effect of age on cancer-specific mortality in patients with small renal masses: A population-based analysis

The effect of age on cancer-specific mortality in patients with small renal masses: A population-based analysis

Age at diagnosis is a determinant factor of renal cell carcinoma– specific survival in patients treated with nephrectomy

Docetaxel enhances apoptosis and G2/M cell cycle arrest by suppressing mitogen-activated protein kinase signaling in human renal clear cell carcinoma

Contact Info

Product

Resources

About